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Abstract
Background: The widespread distribution of Neisseria gonorrhoeae strains that are resistant to previously used and
clinically implemented antibiotics is a significant global public health problem. In line with WHO standards, the
national Gonococcal Antimicrobial Surveillance Programme (RU-GASP) has been in existence in Russia since 2004;
herein, the current status (2015) is described, including associations between N. gonorrhoeae antimicrobial
susceptibility, primary genetic resistance determinants and specific strain sequence types.
Methods: A total of 124 N. gonorrhoeae strains obtained from 9 regions in Russia in 2015 were examined using N.
gonorrhoeae Multi-Antigen Sequence Typing (NG-MAST), an antimicrobial susceptibility test according to European
Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria and an oligonucleotide microarray for the
identification of mutations in the penA, ponA, rpsJ, gyrA and parC genes responsible for penicillin G, tetracycline, and
fluoroquinolone resistance. Genogroup (G) isolates were evaluated based on their porB and tbpB sequence types (STs).
Results: NG-MAST analysis showed a diversified population of N. gonorrhoeae in Russia with 58 sequence types, 35 of
which were described for the first time. The STs 807, 1544, 1993, 5714, 9476 and 12531, which were typical for some
Russian Federation regions and several countries of the former Soviet Union, were represented by five or more isolates.
The internationally widespread ST 1407 was represented by a single strain in the present study. Division into
genogroups facilitated an exploration of the associations between N. gonorrhoeae sequence type, antimicrobial
resistance spectra and genetic resistance determinant contents. Preliminarily susceptible (G-807, G-12531) and resistant
(G-5714, G-9476) genogroups were revealed. The variability in the most frequently observed STs and genogroups in
each participating region indicated geographically restricted antimicrobial susceptibility in N. gonorrhoeae populations.
Conclusions: Resistance or intermediate susceptibility to previously recommended antimicrobials, such as penicillin G
(60.5 %), ciprofloxacin (41.1 %) and tetracycline (25 %), is common in the N. gonorrhoeae population. Based on previous
reports and current data, ceftriaxone and spectinomycin should be recommended for first-line empiric antimicrobial
monotherapy for gonorrhoea in Russia.
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Background
Infections caused by Neisseria gonorrhoeae are signifi-
cant public health problems globally [1], in EU counties
[2, 3], and in the former Soviet Union states [2, 4, 5].
The incidence of gonorrhoea in Russia (146 million in-
habitants) has declined in the past 15 years; however, the
rate of 23.5 reported cases per 100,000 members of the
population is very high for the WHO European Region
[http://data.euro.who.int/cisid/Default.aspx?TabID=394725].
This phenomenon presents with increased urgency
because N. gonorrhoeae has developed resistance to
antimicrobial drugs that were previously and are cur-
rently recommended for gonorrhoea treatment [6]. The
resistance of N. gonorrhoeae to penicillin G is associated
with mutations in the chromosomal ponA and penA
genes, which decrease the affinity of the corresponding
penicillin-binding proteins PBP1 and PBP2 [7, 8]. For
example, an aspartate insertion at amino acid position 345
of PBP2 indicates a significant mutation towards inter-
mediate susceptibility or resistance to penicillin G [8, 9].
The major determinant of tetracycline resistance includes
mutations in the rpsJ gene, which results in the amino acid
substitution V57M or V57L in the ribosomal protein S10
[6, 10]. Resistance to fluoroquinolones is caused by muta-
tions in gyrA and parC genes encoding the gyrase and
topoisomerase polypeptide chains that form the “quin-
olone pocket”. Isolates with high-level fluoroquinolone
resistance may carry several mutations in gyrA at positions
91 and 95 and in parC at positions 87 and 91 [11]. Nu-
merous other chromosomal and plasmid drug resistance
determinants have been described in clinical N. gonor-
rhoeae isolates worldwide [6] following the introduction
of antimicrobials into clinical practice.
In response to this emerging situation, the WHO [12]
and the European Centre for Disease Prevention and Con-
trol [13] published global and region-specific response
plans to mitigate and control the spread of drug-resistant
N. gonorrhoeae. In Russia, the national Gonococcal Anti-
microbial Surveillance Programme (RU-GASP) was initi-
ated in 2004 in accordance with WHO standards.
A key component in these plans and programmes is
to use a number of rapid and sensitive methods to
characterise both the genotypes and drug resistance
phenotypes of N. gonorrhoeae strains. For molecular
epidemiological typing, the N. gonorrhoeae Multi-Antigen
Sequence Typing (NG-MAST) method, which differentiates
strains on the basis of sequence variation in two hypervari-
able porB and tbpB loci, has been used in many countries
worldwide [14–16]. In turn, antimicrobial resistance is trad-
itionally determined using the agar dilution method accord-
ing to the recommendations from the US Clinical and
Laboratory Standards Institute [17]. In 2010–2013, this
approach successfully identified associations between NG-
MAST and antimicrobial resistance profiles to determine
the ability of spreading drug-resistant strains in Poland [3],
Belorussia [5] and Russia [4]. However, the most recent
study on isolates from Russia was internationally published
in 2014, and there are limited data regarding drug resist-
ance determinants in circulating strains; genetic techniques
are increasingly used for this purpose [18, 19].
The aims of this study were to investigate the current
(2015) molecular epidemiology of Neisseria gonorrhoeae
isolates from Russia using the NG-MAST method and
to determine the associations between antimicrobial sus-
ceptibility, the main genetic resistance determinants and
specific strain sequence types.
Methods
Collection and identification of Neisseria gonorrhoeae
isolates
The present study was conducted according to the Russian
Gonococcal Antimicrobial Surveillance Programme (RU-
GASP) in 9 participating regions. The study duration was
from January to December 2015. According to the Russian
Ministry of Health national guidelines № 1177n each pa-
tient signed the informed consent for use of clinical speci-
men in RU-GASP. Urethral and cervical specimens from
females and urethral specimens from males were collected
and cultured on chocolate blood agar supplemented
with 1 % IsoVitaleX enrichment and 1 % VCAT (vanco-
mycin, colistin, amphotericin and trimethoprim) select-
ive supplement (Becton Dickinson, Sparks, MD, USA).
The primary species identification of N. gonorrhoeae was
performed based on Gram staining and rapid oxidase
reaction in participating regions, after which the frozen
samples were transported to the State Research Center
of Dermatovenerology and Cosmetology (Moscow).
Finally, all strains were verified via a sugar utilisation
test performed with an NH ID card for the VITEK 2 Com-
pact analyser (bioMérieux, Marcy l’Etoile, France) and via
MALDI-TOF MS using the MALDI Biotyper (Bruker
Daltonics, Bremen,Germany). The 124N. gonorrhoeae
isolates from females (n = 32) and males (n = 92) were
included in these research, preserved in cryomedium at
-70 °C and then used for DNA extraction and antimicrobial
sensitivity tests.
Neisseria gonorrhoeae genomic DNA isolation and
molecular typing (NG-MAST) protocol
DNA samples for each isolate were prepared from several
N. gonorrhoeae suspensions using the DNA-Express kit
(Lytech, Moscow, Russia) according to the manufacturer’s
instructions and stored at -20 °C for subsequent use.
For molecular typing, the NG-MAST protocol was
performed [20]. More variable internal regions of the
porB and tbpB genes were amplified via PCR, and the
subsequent products were purified and sequenced using
a 3730xl Genetic Analyser (Applied Biosystems, Forster
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City, CA, USA). Both the leading and reverse strands
were assessed; the sequencing data were processed using
3730/3730xl Data Collection Software v3.0. Allele num-
bers for the porB (490 bp) and tbpB (390 bp) sequences
and sequence types were assigned via the online NG-
MAST database (www.ng-mast.net). To define the N.
gonorrhoeae genogroups, the similarities of the porB and
tbpB alleles were determined using the maximum likeli-
hood test and edited using Molecular Evolutionary Genetics
Analysis version 6 (MEGA6) software [21].
Neisseria gonorrhoeae antimicrobial susceptibility testing
The minimum inhibitory concentrations (MICs; mg/L)
of penicillin G, ceftriaxone, tetracycline, spectinomycin,
azithromycin and ciprofloxacin were analysed via the
MIC method using agar dilution methodology on choc-
olate blood agar enriched with 1 % IsoVitaleX (Becton
Dickinson, Sparks, MD, USA) according to the recom-
mendations of the US Clinical and Laboratory Standards
Institute [17].
For quality control, the N. gonorrhoeae ATCC 49226
reference strain was included twice in each test. All
results were interpreted using whole MIC dilutions.
Where available, breakpoints for susceptibility (S), inter-
mediate susceptibility (I) and resistance (R) according to
The European Committee on Antimicrobial Susceptibility
Testing (EUCAST; www.eucast.org) were used (Table 1).
Detection of drug resistance mutations via low-density
oligonucleotide microarray analysis
The N. gonorrhoeae target DNA loci responsible for re-
sistance to beta-lactams, tetracyclines and fluoroquino-
lones were analysed via hybridisation on a low-density
oligonucleotide hydrogel microarray (biochip). The
procedure consisted of two steps: (1) a multiplex PCR
of the penA, ponA, rpsJ, gyrA and parC gene segments
and (2) hybridisation of fluorescently labelled single-
stranded PCR products.
A previously described procedure was used to design
the sequences of primers for amplification and oligonu-
cleotides for immobilisation on the biochip following
their synthesis and purification [22]. The multiplex PCR
procedure is described in Additional file 1 and includes
Table S1 with the sequences of the primers.
The specialised biochip design consisted of 21 ele-
ments with immobilised oligonucleotides (Additional
file 2: Table S2), 3 marker cells for image acquisition
with processing software, and 6 elements of the empty
gel used to calculate the background fluorescence
intensity (Fig. 1a). Gel elements with immobilised oli-
gonucleotides were arranged in groups, each corre-
sponding to an amplified fragment of genomic DNA. In
each group, one element contained an oligonucleotide
with the wild-type sequence, and the other elements
contained oligonucleotides bearing known mutations at
the same position (within 2–5 bp). Perfect or imperfect
hybridisation duplexes were formed in the biochip
elements depending on the nature of the DNA tested.
The procedures for PCR product hybridisation on the
biochip and the processing hybridisation pattern were
performed as previously described [23], facilitating the
sequence determination of specific analysed sites by com-
paring fluorescence signals from immobilised oligonucleo-
tide probes for each group. The hybridisation patterns
corresponding to wild-type and multiple drug resistance
mutations in N. gonorrhoeae are shown in Fig. 1b and c,
respectively.
Results
Molecular typing of Neisseria gonorrhoeae isolates
The study was performed with 124N. gonorrhoeae iso-
lates submitted from 9 regions of the Russian Feder-
ation over a 12-month period in 2015. These strains
(one isolate per patient) were collected from the genital
specimens of 92 (74.2 %) men and 32 (25.8 %) women
and then identified as N. gonorrhoeae based on the
presentation of typical colonies on selective agar media,
visualisation of Gram-negative diplococci via microscopy,
biochemical activity and MALDI-TOF MS spectra.
The sequencing procedure with bacterial DNA ex-
tracts revealed 52 porB and 27 tbpB allele numbers. All
these sequences were checked via the online NG-MAST
database, and 22 porB and 7 tbpB nucleotide sequences
that were described for the first time were uploaded for
Table 1 Antimicrobial susceptibility of 124 Neisseria gonorrhoeae isolates from Russia in 2015
Antimicrobials
(breakpoints; mg/L) a
Number (%) of isolates
Susceptible (S) Intermediate susceptible (I) Resistant (R) Not susceptible (I + R)
Penicillin G (S≤ 0.06, R > 1.0) 49 (39.5) 74 (59.7) 1 (0.8) 75 (60.5)
Ceftriaxone (S≤ 0.125, R > 0.125) 123 (99.2) 0 1 (0.8) 1 (0.8)
Tetracycline (S≤ 0.5, R > 1.0) 93 (75.0) 10 (8.1) 21 (16.9) 31 (25.0)
Spectinomycin (S ≤ 64, R > 64) 124 (100) 0 0 0
Azithromycin (S ≤ 0.25, R > 0.5) 118 (95.2) 4 (3.2) 2 (1.6) 6 (4.8)
Ciprofloxacin (S≤ 0.03, R > 0.06) 73 (58.9) 1 (0.8) 50 (40.3) 51 (41.1)
a according to EUCAST (www.eucast.org)
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new allele number assignation. The most frequently
observed sequences included porB [5619 (n = 14), 37
(n = 13), 738 (n = 7), and 7325 new (n = 6)] and tbpB
[27 (n = 30), 4 (n = 20), and 6 (n = 20)].
According to the NG-MAST protocol for both the porB
and tbpB alleles, a total of 58 sequence types (STs) were
identified and checked via the online database. The preva-
lence of previously unknown STs was determined, and 35
novel ST numbers (12444–12451, 12524, 12528–12532,
12539, 12540, 12555–12560, 12599–12603, 13054–13061)
were obtained from the administrator section of the
NG-MAST website. Among the new STs, the majority
emerged as combinations of known and novel porB and
tbpB alleles, whereas four STs were absolutely unique:
12447 (porB 7287 allele and tbpB2098 allele), 12451
(porB 7290 allele and tbpB 2098 allele), 13059 (porB
7590 allele and tbpB 2256 allele), and 13060 (porB 7591
allele and tbpB 2257 allele).
Additionally, 23 clusters (two or more N. gonorrhoeae
isolates with the same NG-MAST) were identified,
whereas 35 STs were represented by single strains. The
most frequently observed types (represented by 5 or
more isolates) were previously described [9476 (n = 14),
807 (n = 10), 1544 (n = 6), 5714 (n = 6) and 1993 (n = 5)],
whereas most of the new STs were represented in 1–2
isolates, and only 12531 reached 6 strains.
Further data analysis of porB and tbpB allele hom-
ology (the maximum likelihood test [24]) showed the
phylogenetic relationships between certain STs, clus-
tered into ‘genogroups’, comprising the closely related
NG-MAST types. Genogroups (G) were named after
the most frequently occurring ST within the group
(e.g., in G-9476, 52 % were ST 9476, including 11 other
STs and consisting of a total of 27 strains). Four major
genogroups, G-12531 (11 STs, 19 strains), G-9476 (12
STs, 27 strains), G-5714 (14 STs, 30 strains), G-807 (13
STs, 37 strains), and the small G-13056 genogroup, which
includes 4 new STs and was representative of 5 strains,
were defined (Fig. 2), encompassing 118 (95.2 %) of the
total 124 isolates tested.
Antimicrobial susceptibility of N. gonorrhoeae isolates
The results of the antimicrobial susceptibility testing of
all 124 isolates are summarised in Table 1. Of the total
isolates, I + R status to penicillin G was more common
in N. gonorrhoeae; of which 59.7 % (74 of 124) demon-
strated intermediate susceptibility and 0.8 % (1 of 124)
were resistant strains. Furthermore, high resistance was
Fig. 1 Analysis of N. gonorrhoeae drug resistance mutations via hybridisation on a microarray. a Hybridisation microarray configuration.
Immobilised oligonucleotide probes targeted the insertion of D345 in the penA gene, L421P mutation in the ponA gene, 2 mutations
(V57M and V57L) in the rpsJ gene, S91F, D95N, D95G mutations in the gyrA gene, and 7 mutations (S87N, S87R, S87R2, E91Q, E91G, E91K
and E91A) in the parC gene. Elements with wild-type-sequence oligonucleotide probes are depicted with bold circles. M—marker ele-
ments with fluorescent label, 0—reference gel elements without oligonucleotides. b Hybridisation analysis of the wild-type N. gonorrhoeae
DNA sample. c Hybridisation of a DNA sample containing the following mutations: D345 insertion (penA), L421P (ponA), V57M (rpsJ), and
S91F (gyrA). Groups with detected mutations are depicted as boxes
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detected against ciprofloxacin (40.3 %; 50 of 124), whereas
only 1 isolate (0.8 %) showed intermediate susceptibility to
this antimicrobial. The overall number of tetracycline-
resistant N. gonorrhoeae isolates was 21 (16.9 %), which
was accompanied by 10 (8.1 %) strains of intermediate
susceptibility. Among the 124 tested isolates, 2 (1.6 %)
were resistant and 4 (3.2 %) demonstrated intermediate
susceptibility to azithromycin. Finally, 1N. gonorrhoeae
strain only was resistant (MIC = 0.25 mg/L) to ceftriax-
one. Because usual N. gonorrhoeae sensitivity to this
antibiotic is still quite high: 87 % (108 of 124) strains
characterized by the MIC values 0.002–0.008 mg/L, we
described additionally some isolates with reduced sen-
sitivity (MIC = 0.06 mg/L) as indicators of developing
resistance to ceftriaxone. No isolates resistant to spec-
tinomycin were identified.
Of the total N. gonorrhoeae isolates, 2 (1.6 %) multi-drug
resistance strains was defined as strictly resistant to 3 or
more antimicrobials according to EUCAST criteria, while
other 26 (21.0 %) strains were not susceptible (I + R) to 3–4
antimicrobials. One third of all the studied strains (42 of
124; 33.9 %) were susceptible to all tested antimicrobials.
Fig. 2 Dendrogram showing isolate similarity in porB and tbpB alleles (using the maximum likelihood test), sequence types and antimicrobial
susceptibility associations. Designations: gaps in the columns indicate the wild-type/susceptible strain; R—resistance; I—intermediate susceptibility;
S—susceptibility; RIS, RS, RI, IS—variable susceptibility of strains in the NG-MAST cluster; lessS—decreased susceptibility; points with ‘•’ indicate
mutations in the penA, ponA, rpsJ, gyrA and parC genes (v—variable into NG—MAST cluster); *—multi-drug-resistant sequence types
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Antimicrobial resistance genetic determinants of N.
gonorrhoeae isolates
Data obtained from the molecular typing, antimicrobial
susceptibility testing and biochip analysis for each strain
are listed in Additional file 3: Table S3.
The chromosomally mediated determinant most fre-
quently detected was D345 in the penA gene, which en-
codes PBP2 and confers resistance to beta-lactams. This
mutation appeared in 98 of 124 (79.0 %) N. gonorrhoeae
strains, whereas the L421P mutation in the ponA gene,
which also affects susceptibility to beta-lactams, was
revealed to be twice as rare (47 strains; 37.9 %). Forty-
four V57M and six V57L mutations in the rpsJ gene,
responsible for resistance to tetracyclines, were detected
in 50 (40.3 %) isolates. Similar frequencies were shown
for S91F (47 strains; 37.9 %) and D95G (42 strains;
33.9 %) in gyrA gene, which is involved in resistance to
fluoroquinolones (i.e., ciprofloxacin), whereas both mu-
tations were present in 40 strains (32.3 %). On the other
hand, the D95N mutation in the gyrA gene was rare and
appeared in only 2 strains (in both cases in association
with S91F). The S87R mutation in the parC gene, which
is also involved in resistance to fluoroquinolones, was
found in 42 (33.9 %) isolates; this mutation is most typ-
ically combined with mutations in the gyrA gene. In
contrast, E91G was found in only 2 isolates, and the
S87N, E91Q, E91K, and E91A mutations were absent.
Sequence type and antimicrobial resistance associations
A subsequent analysis showed relationships between the
antimicrobial susceptibility results and certain sequence
types in the described N. gonorrhoeae genogroups (Fig. 2).
The G-12531 genogroup was not associated with high-
level antimicrobial resistance and was characterised by a
low frequency of all revealed genetic determinants. Most
typically, isolates from this genogroup (i.e., the ST 12531
cluster) carried a D345 (penA) mutation that led to
intermediate susceptibility to penicillin G. The most
resistant member in this genogroup was an ST 12449
single strain, which showed intermediate susceptibility
to penicillin G (MIC = 0.5 mg/L) and signs of decreased
susceptibility to ceftriaxone (MIC = 0.06 mg/L), as well
as resistance to tetracycline (MIC = 2.0 mg/L) and cipro-
floxacin (MIC = 16 mg/L). This strain carried the major-
ity of the revealed mutations, specifically D345 (penA),
L421P (ponA), V57M (rpsJ), S91F and D95G (gyrA), and
S87R (parC), which were rare in their neighbours’ STs.
The members of G-9476 genogroup (with the excep-
tion of STs 1580 and 11335) showed intermediate
susceptibility to penicillin G, high resistance to cipro-
floxacin, and, in some NG-MAST types, resistance or
intermediate susceptibility to tetracycline that may be
associated with high rate of corresponding mutations.
The most frequently occurring ST cluster, 9476, with 14
isolates, was variable in terms of its antimicrobial resist-
ance spectra: 11 strains shared D345 (penA), L421P
(ponA), V57M (rpsJ), S91F and D95G (gyrA), and S87R
(parC) mutations, whereas 2 strains had no V57M and 1
had no L421P determinants. Notably, the same variability
appeared in some other clusters within other genogroups.
The most numerous ST 5714 cluster and the neigh-
bouring ST1993 cluster in the G-5714 genogroup were
variables in susceptibility to antimicrobials and drug
resistance determinant contents; however, 15 isolates of
9 related STs carried numerous mutations and showed
high-level drug resistance. First of all, this refers to the
ST 1407-related sequence types, including the STs
12556, 12446 and 12450. The ST 1407 was previously
evaluated as an internationally spread MDR N. gonor-
rhoeae clone [9, 14, 25], and in this study, one carried
D345 (penA), L421P (ponA), V57M (rpsJ), S91F and
D95G (gyrA), and S87R (parC) mutations, which corre-
lated with reported data [7] and led to intermediate sus-
ceptibility to penicillin G and resistance to tetracycline
and ciprofloxacin. Moreover, 2 strains in STs 12446 and
12556—closely related to ST 1407, which inherited these
mutations—exhibited MDR. Additionally, one isolate in
the ST12446 cluster showed decreased susceptibility to
ceftriaxone (MIC = 0.06 mg/L).
G-807 had the most STs that were susceptible to anti-
microbials, and the frequency of drug resistance deter-
minants was very low in this large genogroup. Only the
D345 (penA) mutation was preliminarily detected (36 of
37 isolates) to have intermediate susceptibility to penicil-
lin G in most STs. All G-807 genogroup isolates were
susceptible to tetracycline and azithromycin, and 3 only
STs were resistant to ciprofloxacin (i.e., ST 12555 due to
the S91F, D95G and S87R mutations). Moreover, G-807
had a single ST 9480 strain with resistance to ceftriax-
one (MIC = 0.25 mg/L), accompanied by intermediate
susceptibility to penicillin G and ciprofloxacin.
The G-13056 genogroup was small (4 STs of 5 isolates)
but unique and consisted only of the first described STs.
The D345 (penA), L421P (ponA), V57M (rpsJ) and S91F
(gyrA) determinants were typical for the G-13056 members,
whereas the rare mutations D95N (gyrA) and E91G (parC)
were revealed in ST 12528. Moreover, all members of this
unique genogroup carried porB mutation for amino acids
101 (Q→N) and 102 (R→Y) which may be additive for
drug resistance phenomena. As a result, all examples of G-
13056 genogroup were ciprofloxacin-resistant and not
susceptible (I or R) to penicillin G and tetracycline.
Distribution of NG-MAST sequence types in participating
regions of the Russian Federation and regional variability
in N. gonorrhoeae antimicrobial resistance
Only 3 STs (807, 1993 and 5714) were widespread in
at least three of the participating regions, whereas
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considerable diversity in N. gonorrhoeae STs was
observed between regions, and the predominant types
or genogroups were detected in each region. Figure 3
shows the most frequently occurring STs for participating
regions that were accompanied by significant variations in
antimicrobial susceptibility in N. gonorrhoeae populations.
The most closely related samples were obtained from
the Penza region, in which only susceptible ST 9570 was
found. A low level of N. gonorrhoeae antimicrobial re-
sistance was also detected in the Bryansk region, in
which three types (STs 807, 5792 and new 13054) were
predominant. The Cheboksary region had the common
STs 807, 1993 and other N. gonorrhoeae isolates, half of
which were sensitive to all tested antimicrobials. In the
Arkchangelsk region, the STs 807, 1544, 9476 and 12531
were predominant, of which 10.9 % of the strains were not
susceptible (I + R) to three or more antimicrobials but
37.5 % were completely susceptible. Moreover, 1 strain
resistant to ceftriaxone was revealed in the Arkchangelsk
region. The highest variety of STs was identified in the
Kaluga region, in which each strain was represented by an
individual sequence type and 33 % of the isolates were not
susceptible to several antimicrobials, including the 1407
sequence type. In the Kazan region, many isolates were
closely related, and the most frequently occurring were
the first-described STs 12445 and 12448; therefore, the
proportion of non-susceptible isolates was significant
(50 %). Multi-drug-resistant N. gonorrhoeae isolates are
absent in the European part of Russia.
The N. gonorrhoeae isolates from the Siberian part of
Russia were very different from those in the regions
described above. In the Tomsk region, the susceptible
G-5714 genogroup was prevalent; whereas the ST 12556-
related MDR isolate was also identified in this region. The
N. gonorrhoeae isolates from the Novosibirsk region were
closely genetically linked, and the majority of the strains
were related to the unique G-13056 genogroup. In turn,
the prevalence of the G-5714 sequence types was observed
in the Omsk region, in which the ST 12446 was more
common. Due to the high frequencies of antibiotic resist-
ance, genetic determinants in these genogroups and
certain STs, the isolates that were not susceptible (I + R)
to three or more antimicrobials were widespread in the
Omsk and Novosibirsk regions: 56.3 and 71.4 %, respect-
ively (Fig. 3). Moreover, 1 MDR strain and 3 isolates with
decreased susceptibility to ceftriaxone were revealed in
the Omsk region.
The obtained results indicate N. gonorrhoeae epidemi-
ology in Russia as geographically restricted, where signifi-
cant variations in the most frequently observed STs and
genogroups in each of the participating regions led to
differences in antimicrobial resistance for each regional
gonococcal population.
Discussion
The present study examined molecular epidemiological
characteristics (NG-MAST), susceptibility to penicillin G,
ceftriaxone, tetracycline, spectinomycin, azithromycin, and
Fig. 3 Most frequently observed STs or genogroups in each participating region and antimicrobial resistance in the N. gonorrhoeae populations.
Designations: green sectors—susceptible isolates (%); yellow sectors—strains not susceptible (I + R) to 1–2 antimicrobials (%); blue sectors—strains
not susceptible (I + R) to 3 or more antimicrobials (%); red sectors—multi-drug-resistant isolates (%). The map of Russia was taken from
https://commons.wikimedia.org/wiki/File:Blank_Map_-_RussiaFederalSubjects_2007-07.svg source
Kubanov et al. BMC Infectious Diseases  (2016) 16:389 Page 7 of 10
ciprofloxacin, and a spectrum of genetic determinants
within the penA, ponA, rpsJ, gyrA, and parC loci in N.
gonorrhoeae strains isolated in 9 regions of Russia in 2015.
The NG-MAST analysis showed a diversified population
of N. gonorrhoeae in Russia with 58 different sequence
types among the 124 examined gonococcal isolates, 23 of
which were represented by two or more strains; and only
6 STs (807, 1544, 1993, 5714, 9476 and 12531) were repre-
sented by five or more isolates. The STs 807, 1993 and
5714 have been widespread in Russia since 2011–2012 [4];
in the present study, these sequence types were still spread
throughout at least three participating regions, indicat-
ing large sexual transmission chains. Interestingly,
ST807 and ST1993 were revealed as predominant clus-
ters in Belorussia [5] and were detected in Kazakhstan
[26], which shows the spread of some N. gonorrhoeae
clones in the former Soviet Union states. However, STs
typical for EU counties were rare in the present study,
e.g., the internationally spread multi-drug-resistant
gonococcal clone ST1407 [9, 14, 25] was established in
only one isolate. Finally, most STs evolved locally in
Russia, and predominant N. gonorrhoeae molecular types
were shown in most participating regions. Nevertheless,
further data analysis of the homology of the porB and tbpB
alleles established 5 related ‘genogroups’, which demon-
strates the molecular phylogeny of N. gonorrhoeae popula-
tion in Russia.
Divisions into genogroups enabled a more robust ana-
lysis and exploration of the associations between sequence
type and antimicrobial resistance in N. gonorrhoeae. The
G-12531 and G-807 genogroups were characterised by a
low distribution of antimicrobial resistance genetic deter-
minants and included few drug-resistant gonococcal iso-
lates. In contrast, the G-9476 and G-5714 genogroups
demonstrated numerous determinants, and the closely re-
lated NG-MAST sequence types were found to possess
highly similar patterns of drug resistance. The most sig-
nificant observations included the ST 1407-related first-
described STs 12446, 12450 and 12556, which shared
numerous mutations that together conferred multi-
drug-resistance. Surprisingly, in some cases (STs 1933,
5714, 9476), the isolates of one NG-MAST cluster had
variability in terms of their mutation spectra and anti-
microbial susceptibility, which was previously shown in
N. gonorrhoeae isolates from San Francisco, California
[27]. This result confirmed that although NG-MAST
data may provide valuable information regarding a
particular isolate’s antimicrobial susceptibilities, this in-
formation is by no means definitive.
The phenotypic antimicrobial susceptibility tests showed
high N. gonorrhoeae resistance or intermediate susceptibil-
ity to previously recommended empiric first-line therapy
antimicrobials, such as penicillin G (60.5 %), ciprofloxacin
(41.1 %), and tetracycline (25 %), which strongly correlated
with the current widespread antimicrobial resistance
genetic determinants in gonococcal population in Russia.
Drug-resistant gonococcal isolates in Russia were found
in previous studies [4, 28]; however, the rates of antimicro-
bial resistance were significantly higher. This result may
indicate that penicillin G, ciprofloxacin and tetracycline
have not been used to treat gonorrhoea in many years;
however, we did not register a complete recovery of N.
gonorrhoeae susceptibility to these antimicrobials and
revealed the persistence of antimicrobial resistance genetic
determinants without antibiotic selection pressure.
Resistance or intermediate susceptibility to azithro-
mycin was relatively low (4.8 %) in the present study;
previously (in 2011–2012), azithromycin resistance was
observed in N. gonorrhoeae isolates in Russia more
higher (16.5–17 %) [4], which provided an opportunity
to return to azithromycin for the treatment of gonococ-
cal infections in clinical cases with laboratory-proven
N. gonorrhoeae susceptibility.
Spectinomycin-resistant N. gonorrhoeae related to 32
different STs were detected in some regions of Russia in
our previous studies [29, 30]. The present study did not
find spectinomycin-resistant or intermediate susceptibil-
ity gonococcal isolates; consequently, this antimicrobial
is currently listed for the alternative treatment of gonor-
rhoea in Russia when the patient suffers from a severe
beta-lactam allergy.
Using the European EUCAST breakpoint, only 1 (0.8 %)
N. gonorrhoeae strain was resistant to ceftriaxone (MIC >
0.125 mg/L), and 3 (2.4 %) showed decreased susceptibility
(MIC = 0.06 mg/L) to this antimicrobial in 2015. Thus, the
decreasing susceptibility to the “last-line” third generation
cephalosporins observed in EU countries [6, 7, 9] remains
rare in Russia, and we have not reported high-level resist-
ance to ceftriaxone leading to clinical treatment failure.
Based on the previously reported [4, 28–31] and
current data, ceftriaxone should be recommended for
first-line empiric antimicrobial monotherapy for gonor-
rhoea in Russia, which is in line with the European [31]
treatment guidelines. However, the transboundary migra-
tion of N. gonorrhoeae epidemic strains (ST1407 foremost)
and the appearance of new ceftriaxone-resistant strains [6]
warrants the proper use and close control of cephalosporins
to optimise efficacy.
Conclusions
This study of the N. gonorrhoeae population in the
Russian Federation showed predominant resistance or
intermediate susceptibility to previously recommended
antimicrobials, such as penicillin G, ciprofloxacin and
tetracycline. Based on these data, ceftriaxone and spec-
tinomycin are recommended for first-line empirical anti-
microbial monotherapy for gonorrhoea. The continuation
of the RU-GASP monitoring programme is important for
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controlling the spread of drug-resistant N. gonorrhoeae
isolates in Russia.
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